RECRUITING

Imaging Depression in Parkinson's Disease

Talk to us

Conditions

Parkinson's DiseaseMajor Depressive DisorderImaging

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

Official Title

Identifying the Neural Basis of Depression in Parkinson's Disease

Quick Facts

Study Start:2024-09-01
Study Completion:2029-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06402955

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age 40-80.
  2. 2. Physically healthy by medical history, physical, ECG and laboratory examinations
  3. 3. For women of reproductive potential, a negative pregnancy test at screening and scanning
  4. 4. For PD patients, clinical diagnosis of PD, able to consent and tolerate PET procedures
  5. 5. For PD depression patients - at least moderate symptom severity as determined by a cut-off of 14 on the HAMD-17, which has shown maximum discrimination between depressed and non-depressed PD patients87.
  1. 1. Dementia (Montreal Cognitive Assessment (MoCA) score \<21)88
  2. 2. A significant primary DSM-5 psychiatric disorder except for MDD
  3. 3. A history of or current significant medical (e.g. cardiovascular, renal), or neurological (e.g. cerebrovascular, seizure, traumatic brain injury) illness other than PD that is unstable and significantly increase their risk and/or might affect the study objectives, as determined by study physicians.
  4. 4. Prior radiation exposure for research purposes within such that participation in this study would place them over FDA limits for annual radiation exposure
  5. 5. Medications affecting SV2A availability (e.g. levetiracetam)
  6. 6. For dPD patients receiving ketamine, blood pressure \>145/90.
  7. 7. Contraindications to MRI.
  8. 8. Iodine allergy
  9. 9. Bleeding disorder or thinning blood medication
  10. 10. Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.

Contacts and Locations

Study Contact

Sophie Holmes
CONTACT
2036854066
sophie.holmes@yale.edu
Libby DiDomizio
CONTACT
2039476313
libby.didomizio@yale.edu

Study Locations (Sites)

Yale University
New Haven, Connecticut, 06520
United States

Collaborators and Investigators

Sponsor: Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-01
Study Completion Date2029-12

Study Record Updates

Study Start Date2024-09-01
Study Completion Date2029-12

Terms related to this study

Keywords Provided by Researchers

  • Imaging

Additional Relevant MeSH Terms

  • Parkinson's Disease
  • Major Depressive Disorder